Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Lok Lam NgaiConnie Y MaOrla MaguireAn D DoAlberto RobertAaron C LoganElizabeth A GriffithsMichael J NemethCherie GreenTony PourmohamadBo J van KuijkAlexander N SnelZinia W KwidamaBianca Venniker-PuntJames CooperMarkus G ManzBjørn T GjertsenLinda SmitGert J OssenkoppeleJeroen J W M JanssenJacqueline CloosTeiko SumiyoshiPublished in: European journal of haematology (2021)
C-lectin-like molecule 1 bimodality occurs in about 25% of AML patients and the CLL-1- cell population still contains malignant cells, hence it may potentially limit the effectiveness of CLL-1-targeted therapies and warrant further investigation.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- systematic review
- randomized controlled trial
- poor prognosis
- stem cells
- induced apoptosis
- risk assessment
- patient reported outcomes
- long non coding rna
- cell therapy
- bone marrow
- acute lymphoblastic leukemia
- signaling pathway
- endoplasmic reticulum stress
- mesenchymal stem cells
- binding protein
- electronic health record
- pi k akt